Skip to main content
Erschienen in: Tumor Biology 2/2013

01.04.2013 | Research Article

Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer

verfasst von: Kai-Yu Han, Xin Gu, Hao-Ran Wang, Dong Liu, Fu-Zhen Lv, Jia-Ning Li

Erschienen in: Tumor Biology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to detect MAC30 expression in human non-small cell lung cancer (NSCLC) and to analyze its association with prognosis of NSCLC patients. Quantitative real-time RT-PCR was performed to examine the expression of MAC30 mRNA in 20 cases of NSCLC and corresponding non-tumor tissue samples. Immunohistochemistry was performed to detect the expression of MAC30 in 95 NSCLC tissues. We found that the expression levels of MAC30 mRNA in NSCLC tissues were significantly higher than those in corresponding non-tumor tissues. High-level MAC30 expression was correlated with poor tumor differentiation, TNM stage, and lymph node metastasis. Patients with high expression levels of MAC30 showed lower overall survival rate than those with low expression levels. Multivariate analysis showed that high MAC30 protein expression was an independent prognostic factor for NSCLC patients. Our study suggests that over-expression of MAC30 may play an important role in the progression of NSCLC and MAC30 expression may offer a valuable marker for predicting the outcome of patients with NSCLC.
Literatur
2.
Zurück zum Zitat Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50. doi:10.1200/JCO.2005.05.2308.PubMedCrossRef Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50. doi:10.​1200/​JCO.​2005.​05.​2308.PubMedCrossRef
3.
Zurück zum Zitat Murphy M, Pykett MJ, Harnish P, Zang KD, George DL. Identification and characterization of genes differentially expressed in meningiomas. Cell Growth Differ. 1993;4:715–22.PubMed Murphy M, Pykett MJ, Harnish P, Zang KD, George DL. Identification and characterization of genes differentially expressed in meningiomas. Cell Growth Differ. 1993;4:715–22.PubMed
4.
Zurück zum Zitat Malhotra K, Luehrsen KR, Costello LL, Raich TJ, Sim K, Foltz L, et al. Identification of differentially expressed mRNAs in human fetal liver across gestation. Nucleic Acids Res. 1999;27:839–47.PubMedCrossRef Malhotra K, Luehrsen KR, Costello LL, Raich TJ, Sim K, Foltz L, et al. Identification of differentially expressed mRNAs in human fetal liver across gestation. Nucleic Acids Res. 1999;27:839–47.PubMedCrossRef
5.
Zurück zum Zitat Kayed H, Kleeff J, Ding J, Hammer J, Giese T, Zentgraf H, et al. Expression analysis of MAC30 in human pancreatic cancer and tumors of the gastrointestinal tract. Histol Histopathol. 2004;19:1021–31.PubMed Kayed H, Kleeff J, Ding J, Hammer J, Giese T, Zentgraf H, et al. Expression analysis of MAC30 in human pancreatic cancer and tumors of the gastrointestinal tract. Histol Histopathol. 2004;19:1021–31.PubMed
6.
Zurück zum Zitat Potapova O, Anisimov SV, Gorospe M, Dougherty RH, Gaarde WA, Boheler KR, et al. Targets of c-Jun NH(2)-terminal kinase 2-mediated tumor growth regulation revealed by serial analysis of gene expression. Cancer Res. 2002;62:3257–63.PubMed Potapova O, Anisimov SV, Gorospe M, Dougherty RH, Gaarde WA, Boheler KR, et al. Targets of c-Jun NH(2)-terminal kinase 2-mediated tumor growth regulation revealed by serial analysis of gene expression. Cancer Res. 2002;62:3257–63.PubMed
7.
Zurück zum Zitat Sobin LH, Fleming ID. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. TNM classification of malignant tumors, fifth edition. Cancer. 1997;80:1803–4.PubMedCrossRef Sobin LH, Fleming ID. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. TNM classification of malignant tumors, fifth edition. Cancer. 1997;80:1803–4.PubMedCrossRef
8.
Zurück zum Zitat Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.PubMedCrossRef Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.PubMedCrossRef
9.
Zurück zum Zitat Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210–8.PubMed Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210–8.PubMed
10.
Zurück zum Zitat Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004;5:341–53.PubMedCrossRef Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004;5:341–53.PubMedCrossRef
11.
Zurück zum Zitat Xiao M, Li H, Yang S, Huang Y, Jia S, Wang H, et al. Expression of MAC30 protein is related to survival and clinicopathological variables in breast cancer. J Surg Oncol. 2012. doi:10.1002/jso.23269. Xiao M, Li H, Yang S, Huang Y, Jia S, Wang H, et al. Expression of MAC30 protein is related to survival and clinicopathological variables in breast cancer. J Surg Oncol. 2012. doi:10.​1002/​jso.​23269.
12.
Zurück zum Zitat Zhao ZR, Zhang LJ, He XQ, Zhang ZY, Zhang F, Li F, et al. Significance of mRNA and protein expression of MAC30 in progression of colorectal cancer. Chemotherapy. 2011;57:394–401.PubMedCrossRef Zhao ZR, Zhang LJ, He XQ, Zhang ZY, Zhang F, Li F, et al. Significance of mRNA and protein expression of MAC30 in progression of colorectal cancer. Chemotherapy. 2011;57:394–401.PubMedCrossRef
13.
Zurück zum Zitat Yan BY, Wang DW, Zhu ZL, Yang YH, Wang MW, Cui DS, et al. Overexpression of MAC30 in the cytoplasm of oral squamous cell carcinoma predicts nodal metastasis and poor differentiation. Chemotherapy. 2010;56(6):424–8.PubMedCrossRef Yan BY, Wang DW, Zhu ZL, Yang YH, Wang MW, Cui DS, et al. Overexpression of MAC30 in the cytoplasm of oral squamous cell carcinoma predicts nodal metastasis and poor differentiation. Chemotherapy. 2010;56(6):424–8.PubMedCrossRef
14.
Zurück zum Zitat Zhang ZY, Zhao ZR, Adell G, Jarlsfelt I, Cui YX, Kayed H, et al. Expression of MAC30 in rectal cancers with or without preoperative radiotherapy. Oncology. 2006;71:259–65.PubMedCrossRef Zhang ZY, Zhao ZR, Adell G, Jarlsfelt I, Cui YX, Kayed H, et al. Expression of MAC30 in rectal cancers with or without preoperative radiotherapy. Oncology. 2006;71:259–65.PubMedCrossRef
15.
Zurück zum Zitat Moparthi SB, Arbman G, Wallin A, Kayed H, Kleeff J, Zentgraf H, et al. Expression of MAC30 protein is related to survival and biological variables in primary and metastatic colorectal cancers. Int J Oncol. 2007;30(1):91–5.PubMed Moparthi SB, Arbman G, Wallin A, Kayed H, Kleeff J, Zentgraf H, et al. Expression of MAC30 protein is related to survival and biological variables in primary and metastatic colorectal cancers. Int J Oncol. 2007;30(1):91–5.PubMed
Metadaten
Titel
Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer
verfasst von
Kai-Yu Han
Xin Gu
Hao-Ran Wang
Dong Liu
Fu-Zhen Lv
Jia-Ning Li
Publikationsdatum
01.04.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0612-z

Weitere Artikel der Ausgabe 2/2013

Tumor Biology 2/2013 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.